title: Recent androgen receptor antagonists in prostate cancer.
abstract: Androgen receptor has been shown to promote prostate cell growth and carcinogenesis of prostate cancer by up-regulating its target genes. Testosterone and dihydrotestosterone are two major hormones which bind to and activate androgen receptor. Targeting both the androgen receptor and the enzymes catalyzing the biosynthesis of testosterone and dihydrotestosterone has been shown to be clinically beneficial in the treatment of prostate cancer. Prostate cancer can become castration-resistant after long term treatment with chemo drugs, so efforts in finding compounds with improved efficiency to castration-resistant prostate cancer are urgently needed. In this review we summarized the studies on recent progress in the development of small molecular AR antagonists for the treatment of prostate cancer.
authors: Xufang
authors: X
authors: Lu
authors: Kang
authors: K
authors: Dun
authors: Yang
authors: Y
authors: Wang
authors: Yong
authors: Y
authors: Yang
authors: Qidong
authors: Q
authors: You
authors: Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China. zhiyuli@cpu.edu.cn.
authors: Zhiyu
authors: Z
authors: Li
mesh_terms: D059002:Androgen Receptor Antagonists / Q000627:therapeutic use*; D016503:Drug Delivery Systems / Q000639:trends*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D054852:Small Molecule Libraries / Q000138:chemical synthesis / Q000627:therapeutic use*
chemical_list: D059002:Androgen Receptor Antagonists; D054852:Small Molecule Libraries